Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha7 nicotinic acetylcholine receptor negative allosteric modulator (Bionomics)
- Development stage
- Preclinical
- Lead developer
- Neuphoria Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Bionomics is developing small molecule negative allosteric modulators (NAMs) of the alpha7 nicotinic acetylcholine receptor (α7 nAChR) for the treatment of various central nervous system (CNS) disorders. Unlike positive allosteric modulators (PAMs) which enhance receptor activity, NAMs reduce the receptor's response to its endogenous ligand, acetylcholine. This mechanism is being explored for conditions where overactivity of the α7 nAChR is implicated. The program is currently in the preclinical lead candidate stage and is part of Bionomics' broader cholinergic platform.
- Other names
- α7 nAChR NAMsalpha7 nAChR negative allosteric modulatorsalpha-7 nAChR negative allosteric modulatorsalpha 7 nAChR negative allosteric modulators
02
Targets
CHRNA7 (α7 nicotinic receptor)
Beyond the preview
Go deeper on alpha7 nicotinic acetylcholine receptor negative allosteric modulator (Bionomics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha7 nicotinic acetylcholine receptor negative allosteric modulator (Bionomics).